Patents Assigned to Hadassah Medical Organization
  • Publication number: 20080085866
    Abstract: Methods for treating a bacterial infection by using a metallo-desferrioxamine complex.
    Type: Application
    Filed: August 13, 2007
    Publication date: April 10, 2008
    Applicants: WASHINGTON, UNIVERSITY OF, HADASSAH MEDICAL ORGANIZATION - HADASIT
    Inventors: E. Greenberg, Ehud Banin, Eyal Banin, Eduard Berenshtein, Mordechai Chevion
  • Patent number: 6348213
    Abstract: A method of-treating a relatively aged animal to reverse age-related changes in the lipid composition of organ and tissue cells, such as heart muscle cells, and the ability of the animal to withstand respiratory stress. A suspension of small unilamellar vesicles composed predominantly of egg phosphatidyl choline is administered parenterally to the animal, preferably over a period of several days and at a dose level of between about 0.1 and 1 grams lipid per kg body weight per day. Changes in the heart muscle cells are reflected in decreased levels of serum creatine phosphokinase. Liposome administration is continued until the serum creatine phosphokinase level drops at least about 50%. Also disclosed are liposome treatment methods for increasing longevity and male fertility.
    Type: Grant
    Filed: May 3, 1994
    Date of Patent: February 19, 2002
    Assignees: Yissum Research and Development Co. of The Hebrew University of Jerusalem, Hadassah Medical Organization
    Inventors: Yechezkel Barenholz, Elishalom Yechiel
  • Patent number: 5362641
    Abstract: The present invention relates to a substantially purified heparanase obtained from the human SK-HEP-1 cell line and a method to purify the heparanase from a centrifuged dialyzed homogenate of the SK-HEP-1 cells or a cell culture medium containing the heparanase from the SK-HEP-1 cell line.
    Type: Grant
    Filed: January 8, 1992
    Date of Patent: November 8, 1994
    Assignee: Hadassah Medical Organization Kiryat Hadassah
    Inventors: Zvi Fuks, Israel Vlodavsky
  • Patent number: 5091626
    Abstract: A method for the ablative reshaping of material surfaces, including the steps of providing a source of an ablative beam having a given average fluence distribution over its cross-sectional extent, determining the ablation curve of the material to be reshaped, selecting, from said ablation curve, an ascending region having an at least approximately constant slope, selecting a beam fluence from among the fluences comprised in said region, irradiating the material surface to be shaped, and controlling the geometry of the material surface thus being reshaped by controlling the total amount of energy per unit area of said surface delivered during said irradiation.
    Type: Grant
    Filed: February 2, 1990
    Date of Patent: February 25, 1992
    Assignees: Hadassah Medical Organization, Israel Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Aaron Lewis, Amihay Fuxbruner, Itzhak Hemo
  • Patent number: 5082851
    Abstract: The invention provides a composition for protecting the heart from myocardial ischemia and reperfusion injury as well as for reducing post-ischemic damage, improving cardiac function and serving as a hypothermic cardiac preservative solution comprising N,N,N'N'-tetrakis-(2-pyridylmethyl)-ethylenediamine (TPEN) as active ingredient therein.
    Type: Grant
    Filed: February 7, 1990
    Date of Patent: January 21, 1992
    Assignees: Hadassah Medical Organization, Yissum Research and Development Corporation of the Hebrew University of Jerusalem
    Inventors: Jerachmiel Y. Appelbaum, Mordechai Chevion, Gideon Uretzky
  • Patent number: 4898735
    Abstract: A drug/liposome composition comprising an aqueous suspension of liposomes and, entrapped in the lipid bilayer region of the liposomes, an anthraquinone drug containing quinone and hydroquinone functionalities on adjacent anthracene rings. An iron-specific trihydroxamic chelating agent contained in the bulk aqueous phase of the suspension and a lipophilic free-radical scavenger contained in the bilayer region of the liposome cooperate to reduce chemical modification of both drug and lipid components of the composition. A preferred composition containing doxorubicin and alpha-tocopherol entrapped in the liposomes, and ferrioxamine in the aqueous suspension phase is effective in treating human neoplasms, with significantly reduced side effects over those produced by free-drug administration.
    Type: Grant
    Filed: October 12, 1988
    Date of Patent: February 6, 1990
    Assignees: Yissum Research and Development Company of the Hebrew University of Jerusalem, Hadassah Medical Organization
    Inventors: Yechezkel Barenholz, Alberto Gabizon
  • Patent number: 4812314
    Abstract: A method of treating a relatively aged animal to reverse age-related changes in the lipid composition of organ and tissue cells, such as heart muscle cells, and the ability of the animal to withstand respiratory stress. A suspension of small unilamellar vesicles composed predominantly of egg phosphatidyl choline is administered parenterally to the animal, preferably over a period of several days and at a dose level of between about 0.1 and 1 grams lipid per kg body weight per day. Changes in the heart muscle cells are reflected in decreased levels of serum creatine phosphokinase. Liposome administration is continued until the serum creatine phosphokinase level drops at least about 50%. Also disclosed are liposome treatment methods for increasing longevity and male fertility.
    Type: Grant
    Filed: February 24, 1986
    Date of Patent: March 14, 1989
    Assignee: Yissum Research & Dev. Co. of the Hebrew Univ. of Jerusalem and Hadassah Medical Organization
    Inventors: Yechezkel Barenholz, Elishalom Yechiel
  • Patent number: 4797285
    Abstract: A drug/liposome composition comprising an aqueous suspension of liposomes and, entrapped in the lipid bilayer region of the liposomes, an anthraquinone drug containing quinone and hydroquinone functionalities on adjacent anthracene rings. An iron-specific trihydroxamic chelating agent contained in the bulk aqueous phase of the suspension and a lipophilic free-radical scavenger contained in the bilayer region of the liposome cooperate to reduce chemical modification of both drug and lipid components of the composition. A preferred composition containing doxorubicin and alpha-tocopherol entrapped in the liposomes, and ferrioxamine in the aqueous suspension phase is effective in treating human neoplasms, with significantly reduced side effects over those produced by free-drug administration.
    Type: Grant
    Filed: December 6, 1985
    Date of Patent: January 10, 1989
    Assignees: Yissum Research and Development Company of the Hebrew University of Jerusalem, Hadassah Medical Organization
    Inventors: Yechezkel Barenholz, Alberto Gabizon
  • Patent number: 4579730
    Abstract: The invention provides a pharmaceutical composition for the oral administration of insulin comprising insulin, a bile acid or alkali metal salt thereof, the bile acid being selected from the group consisting of cholic acid, chenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenocholic acid, 3.beta.-hydroxy-12-ketocholic acid, 12.alpha.-3.beta.-dihydrocholic acid, and ursodesoxycholic acid, and a protease inhibitor, the composition being provided with an enterocoating to assure passage through the stomach and release in the intestine.
    Type: Grant
    Filed: May 9, 1984
    Date of Patent: April 1, 1986
    Assignee: Hadassah Medical Organization
    Inventors: Miriam Kidron, Ehud Ziv, Hanoch Bar-On, Amiram Eldor